Burning Rock Biotech/$BNR
1D1W1MYTD1Y5YMAX
About Burning Rock Biotech
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
- Ticker
- $BNR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Guangzhou, China
- Website
- www.brbiotech.com
BNR Metrics
BasicAdvanced
$107M
-
-$0.83
1.33
-
Price and volume
Market cap
$107M
Beta
1.33
52-week high
$41.72
52-week low
$6.79
Average daily volume
7K
Financial strength
Current ratio
3.05
Quick ratio
2.712
Long term debt to equity
5.722
Total debt to equity
9.848
Interest coverage (TTM)
-1,300.24%
Profitability
EBITDA (TTM)
-6.59
Gross margin (TTM)
74.55%
Net profit margin (TTM)
-11.53%
Operating margin (TTM)
-11.37%
Effective tax rate (TTM)
-2.71%
Management effectiveness
Return on assets (TTM)
-4.45%
Return on equity (TTM)
-10.90%
Valuation
Price to revenue (TTM)
1.408
Price to book
0.21
Price to tangible book (TTM)
0.21
Price to free cash flow (TTM)
-18.357
Free cash flow yield (TTM)
-5.45%
Free cash flow per share (TTM)
-0.555
Growth
Revenue change (TTM)
-1.69%
Earnings per share change (TTM)
-75.49%
3-year revenue growth (CAGR)
-3.37%
3-year earnings per share growth (CAGR)
-59.83%
What the Analysts think about BNR
Analyst ratings (Buy, Hold, Sell) for Burning Rock Biotech stock.
BNR Financial Performance
Revenues and expenses
BNR Earnings Performance
Company profitability
BNR News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.